SYNH - Earnings call transcript Q4 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to the Syneos Health Fourth Quarter and Full Year 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time.

I would like to hand the conference over to Ronnie Speight, Senior Vice President of Investor Relations. Please go ahead, sir.

Ronnie Speight

everyone. morning, Good our the Executive on Michelle are Macdonald, Paul Alistair our Solutions. With Jason call Meggs, Chief Colvin, and Solutions; Officer; of Officer; of our our Clinical President me Commercial today President Chief Keefe, Financial

release, the our our on slide presentation at investor.syneoshealth.com. In prepared press corresponding is remarks addition a to available website to

the under constitute growth, and prospects results Private that make forward-looking for Reform XXXX, Remarks statements financial Act we provisions update about any and anticipated future safe purposes Litigation Securities we of the the obligation expectations, company harbor them. plans, of for to disclaim

section differ Actual our the for ended important may statements These Form as December indicated result year and our XX, materially results factor by filings. factors. these in forward-looking other of from those discussed SEC factors XX-K various of are XXXX, a risk the

outside events These for a effects this and replacement we measures consider will exclude During we not GAAP. accordance supplement call, prepared be the our certain non-GAAP which be with and a considered transactions measures measures, should of financial core of to discuss in to non-GAAP operations.

of measures, non-GAAP a directly presentation. GAAP For with the please our appendix the refer the measures comparable to most reconciliation financial of

I to the would call like turn Alistair now to over Macdonald. Alistair?

Alistair Macdonald

morning, for Good joining us everyone, you Ronnie. and thank Thanks, today.

to of the During value the life. fourth quarter, proposition from we awards and our unique power lab speed saw growth, realizing strong revenue net to therapies

the year while closed returning segment year expanding growth Solutions Clinical the market Our strongly, to level profitability. for

pharma position to maintaining ramp up customers. our small continued preferred across large of we in guidance, mid-sized businesses XXXX expect we As new while with as our provider relationships our strength reflected in leadership on both

a by XXXX. customer healthy the new our of the at start record encouraged model including business pipelines and interest further with in across in pipeline Solutions strong segments are Clinical We RFP flow unique continued

performance I Before with a details, key start I’d into to few highlights. the get like

fourth net billion in of the Commercial of the performance aggregate year $X.X record ratio an X.XXx full X.XXx the and with closed quarter we Clinical of book-to-bill Solutions wards awards for resulting year. delivered First, the We X.XXx book-to-bill and ratio Solutions.

Second, Solutions comprised X.X% full in Commercial XXXX of X.X% year or for Clinical currency. constant currency X.X% of in constant or Solutions revenue adjusted constant growth currency or our X.X% increased of growth growth X.X% in the and X.X%

and Third, our progress flow balance we to deployment cash make plans. continue on our improve capital steady

term target. the net During quarter, additional loan we X.Xx fourth $XX of achieving paid leverage out an million debt

to our the XXXX. X.Xx debt. of We focused by further redeem also feature reduce targeting our to draw the end exercised Xx our to notes X.X% reduction our cost senior delayed on leverage A Loan of net Term on remain and debt of We

want finance their Clinical we our reported to efforts the successfully express for particularly weaknesses remediating material our I and a Solutions thanks in Finally, XXXX and those in to internal special teams, in tremendous controls that XX-K.

the year. fourth $X.X our strength turning new pharma were top to to of preferred on continue business. relationships. a X.XXx more billion particular These Clinical the by with we net awards clinical up and book-to-bill provider Now for in of awards delivered awards resulting quarter in in record than as Solutions ramp total ratio broad-based results XX

opportunities X.X% remains record our our Our backlog of pipeline year-over-year grew fueling growth new and expectations. level at a

quarter, year. fourth a the for XXXX ratio of awards of also finished Solutions book-to-bill Commercial with wards net resulting billion in segment and $X.X record Our in the X.XXx

year mid-single opportunities digits in strong, full In we growth it guidance. addition, which how our drive pipeline of our the XXXX remain outlined expect

to the Importantly, progress customers, of mid-sized with on Commercial during we revenue XXXX, of significant in one strategy. our a saw Solutions XX% initiatives small key growth growth demonstrating our

expansion into strong are strategic part of experiencing we market. our growth Europe also as addition, in In that

to continues with offering comprehensive Our resonate and unique timelines. outsourcing development of to product all customers commercialization clinical end-to-end accelerate providing sizes, One solutions development Syneos

relationship One preferred As latest pharma large the utilize portfolio our Syneos assets. of quarter, capabilities we development to last highlighted provider of manage a the

across team managing drive customer Commercial of value to segments Clinical continues is our lifetime a currently our of $X.X strategist and billion. awards asset and projects potential total over One Syneos award with

We life an expect products this provide over the awards cycle. pipeline portfolio product their as to of years move additional these commercial coming through development

leading technology to grow data our bringing and to invest our continued We tech network, Assembly in industry Dynamic enablement model. further and

two During this important the to network. made strategic additions fourth quarter, we

strategic outcomes. Health’s and AI-driven predict with AI trial adherence and AiCure’s AiCure to and patient to combines patient company. proprietary and with advanced collaboration we First, intelligence a insights entered Syneos improve behaviors behavioral into insights This software partnership and data analyze, analytics capture, clinical

advanced tracking CRM the AI announced we and healthcare experience Indegene new Microsoft’s investment underlying believe unique or improves relationships Omnipresence, these management technologies AI power brings customer analytics professionals’ clinical and experiences capabilities. combining capabilities. enable the minority the commercial traditional advanced strategic will with that platform and the further by in to healthcare collaboration end-to-end industry. technologies We omnichannel technology platform and CRM Second, the of and our while This integrated multichannel capabilities

important patients In express like as we products find customers. Health is do we from lab how to in What to distance ways day to QX’s the engage and XX,XXX would just and Syneos our my I every represents shorten colleagues, the the way making providers life. to market sincere my healthcare closing, size difference collaborate with this lives to come gratitude is a plus performance we to to and daily inpatients

financial more me comments let our performance. to Jason Now turn it for Jason? over on

Jason Meggs

morning good and Alistair, you, everyone. Thank

As non-GAAP X. an Slide are basis adjusted on a on results or defined discussed as reminder, all

detail. by me reviewing our results Let begin financial in

quarter compared up quarter currency. XXXX on our revenue the X% $X.XX up of and adjusted constant fourth Slide X, shown for fourth in As the X.X% of XXXX was billion, to

$X.XX X.X% and full the revenue up was adjusted constant XXXX, X.X% currency. up For year billion, in

growth revenue a in for million or by fourth in FX. year-over-year on business new shows the $XXX.X X quarter impact adjusted of revenue was quarter The Clinical Solutions Slide offset fourth higher revenue by the to X.X% that Solutions Clinical basis. awards, the net primarily partially currency driven our X.X% from grew constant

quarter Our clinical to the growth higher largely expenses. exceeded revenue growth our due anticipated in in growth reimbursable fourth

full Clinical currency. XXXX, year or X.X% Solutions constant $X.XX X.X% representing revenue adjusted of billion was the growth For

as to fourth Moving X, declined revenues the project by was segment The declined from the expected, business new revenue our primarily quarter by delays offset quarter the X.X% cancellations earlier from currency. from business decline constant in adherence net and fourth in impact higher Commercial revenue discussed $XXX.X decline partially Slide and previously driven and our XXXX the of to awards. medication during million adjusted year-over-year in commercial revenue in X.X%

the compared fourth and fourth XX $X.XX decline XXXX, benefits X.X% growth year, an Adjusted increased growth in was billion For increase constant by net medication for X% for quarter for margin adherence offset EBITDA our of the in The EBITDA Commercial revenue XXXX. by increase flat. full primarily of of revenue increase When and in year synergies relatively quarter year-over-year by the growth. XXXX points of adjusted timing was partially overall impact a million, our last in in driven $XXX.X of was fourth EBITDA quarter revenue. Solutions of and margin the resulting quarter XX.X% increase expenses highlighted adjusted and basis to realized reimbursable fourth the and adjusted X.X% margin currency to the the EBITDA representing adjusted

full Adjusted million, XX.X%, was compared EBITDA of up XXXX. $XXX.X for the and XX X% points year margin growth XXXX representing basis of to

to We million. $XXX of from merger our million have increased $XXX estimate synergies XXXX for

the $XX million we realized For reinvestments. quarter to the of impact XXXX for total of prior XXXX, to of million fourth bringing strategic our our synergies $XXX

also further model we in leverage. lower-cost labor As and technology organizational which and initiatives operating These additional launched and efficiencies, arbitrage mid-January, highlighted margin from includes formally initiatives series process we operating enhancement in ForwardBound. initiatives call jurisdictions, we automation have other of

million $XX expect XXXX. savings yield ForwardBound run million of rate to exiting We to $XXX an additional

We XXXX these expansion that will increased adjusted margin synergies, points of of ForwardBound, coupled strategic estimate through yield annual points XX least EBITDA with at reinvestments. the basis our impact of basis net to XX merger

EPS fourth to growth the compared by year-over-year, XXXX. EPS lower XXXX grew was quarter, and Adjusted XX.X% and primarily of diluted X.X% EBITDA the year representing $X.XX driven diluted adjusted interest for expense. our by Adjusted of of growth $X.XX for full

cash balance to Slide summarized X. as on turning on sheet Now flow the

had improved compared flow operations the flow from quarter, and quarter to of collections cash operations we During $XXX.X level. XXXX the from Cash fourth primarily performance. fourth of stronger million, record billing a to due

total billion. the unrestricted debt outstanding DSO with for $X.XX XX.X the and cash days. We quarter of million was $XXX.X ended quarter of

cash flow investments, X provides capital and shareholder our remain to repayment, We focused well tuck-in capital market conditions structure. on value. as as management deployment and a to while Slide and repurchases also update approach drive debt deployment acquisitions, our available capital on by activities. determined share balanced includes debt opportunities This as an optimizing

our Loan A $XXX our During cost reduce the executed we and Term quarter, overall further on million notes of redeemed X.X% our to fourth draw senior debt. the delayed feature

to utilize flow of We B, free also repay Term net our an of leverage target million achieving our additional cash Loan $XX X.Xx.

leverage we’re Xx to XXXX. end X.Xx Alistair mentioned, As net also of of the targeting by

through expansion Board Although fourth capacity in $XXX.X a million the outstanding million XXXX. of repurchase now additional also the of totals quarter, end to $XX of our our stock extended repurchase we This term did to the our end the share $XXX utilized be until not repurchase which approved and authorization, shares available of during any leads XXXX. million

tax non-GAAP Our of full was fourth quarter the XX%. XXXX the for rate effective and year

our was cash of outlay benefit of XXXX approximately $XX full NOL given Our the for taxes deductions. the actual year for net million

remediated that part internal As internal process. material weaknesses successfully of report we Alistair the we evaluation are annual highlighted, our to and audit pleased previously controls control had as in disclosed

advisors part environment. I of our and through XXXX our efforts internal the this would sincere thanks tireless of for team express control process their during to as my our work to continued to like strengthening

on now guidance Slide our Turning to X.

we reminder, guidance of in a issued initial mid-January. view As our

year $X billion of to $X.XX X.X% expect $X.XX X.X%. $X.X growth billion billion from to of to to range X.X%. full We of to billion, revenue clinical or commercial XXXX billion includes or revenue growth continue representing and to X.X% X.X% This X.X% growth of billion to $X.XX of to $X.XX our revenue

total and XX from Our X.X% at basis range $XXX approximately to margin of expectations representing $XXX adjusted growth expansion points midpoint. EBITDA the XX.X% to for million of million,

from We $X.XX expect our range adjusted to $X.XX. to EPS

interest of $XXX and million expense guidance Slide XXX.X X, non-GAAP XX% of of As diluted incorporates share million million on rate an a estimated $XXX to effective and our tax shares. outlined count

the want XXXX you provide for commentary quarter, also with expected our to and normal given I profile some seasonality. first growth

We billion, in revenue commercial growth to of to representing of comprised of to X%. X.X% of billion of by to growth This X.X% clinical $X.XX year-over-year decline is X.X% expect revenue $X.XX offset revenue X.X% partially X.X%.

outbreak coronavirus Asia-Pacific on reflects for headwind operations quarter revenue a Clinical of in million representing the million. our impact the our the $X revenue the of to guidance estimate first $XX current of region,

Commercial well revenue the highlighted for adherence quarter medication we and XXXX. as first the from year-over-year headwinds the guidance impact continued as for of the reflects growth of before the business to balance returning delays cancellations previously

year-over-year of representing We to million, million expect growth $XXX total EBITDA of up $XXX adjusted to X.X%.

we’d questions. our prepared completes answer This and be Operator? any happy to remarks

Operator

Instructions] Baird. [Operator Coldwell Our with Eric question comes first from

is now line open. Your

Eric Coldwell

thanks Hey, on steps much. on you’re that on was and growth few expansion you Anything the sizing bit in taking. details that you share a can in the little I business, that more very the a hoping the geography. wanted Europe. in I in could you’re give to commercial investments making dig

you services of what have maybe Thanks compares then suite in And the your in a Europe UK. where and strong want that the with hold, much. very how clients U.S. how lastly,

Alistair Macdonald

morning. Good Eric. Good Thanks, question.

the I in market the think different Europe to in is U.S. commercial landscape commercial in

you all the with in have kind investing of to then in deployment be field because sorts we’re comms, of agreements solutions placement careful and communications, get thing. into Europe co-employment So consulting digital you of that and

country we’ve But by growing slowly that been country.

of in of do. the where Europe of fairly to comparable compared suite in we we’re I what terms in services terms can think U.S.

people that of want because of we’re to think the delivering infrastructure seeing market the that have or starting customers we into One the to pretty are the that and I are U.S. pre-revenue product to and who well organizations, pretty they’re Kong Syneos when what also rules your attracted show and changed product And I Europe get U.S. coming out work Europe? to Syneos as experience investing – in investment attractive the a the in bring model. mean, on One of in actually Asia to lot Michelle, thoughts a China Hong don’t

Michelle Keefe

on to solution. do think we And deployment a desire really are positioned we’re small with communications So commercial right? them. growing Alistair solutions go U.S. to based and Europe, commercial desire seeing markets uniquely businesses that said, in to do into there. And I two and customers, midsize clients a the as integration wanting we’ve integrated to really consulting truly large especially other with of to to buy real our asking in business our the mid Small things, a us been that for

And is where specifically us for asking opportunity we’ve of longstanding customers the the so EU place business U.S. seen X. that’s in the been another to U.S. outside in compete

Eric Coldwell

great. That’s

a as can you are Just talk with you’re recent that and quick business mix what pretty wins Syneos about or is it follow-up, that One, shift you consistent seeing any seeing today? in

Alistair Macdonald

pretty wise seeing. mix consistent we’re I that think it’s

of some customers, device think a the early that just were but I think was coincidence. customers I

in continue we for differentiator something that use interest pretty interest One well small it’s been we seemingly big back has Syneos which as discussions discussions. in as mix the So it as peaks Obviously, with pleased pharma their peaks people’s big a those the to all And wins XXXX, we’re in sorts pharma steady. to about. of mid, have

us, this contracts outsourcing And that I gives in think just market a he we to obviously, a it's go product have before Michelle – that product write tell have do. need like guys people had and the people "I a I that you on one sorry, what and with," said, I'm told that XXX hire could I So I or development to CEO contract "I thought a XX I'm in package you with." everything with from you write said, they could

that it's a with do different – of individual model writing business contracts. that's a enables model of hundreds kind to it's easier So than

So it. think any I don't But shift resonates it mix well. pretty we've seen in

Eric Coldwell

Thanks Okay, good. others. the will very much. I seed

Alistair Macdonald

Eric. Thanks,

Jason Meggs

you. Thank

Operator

you. Thank

with from question Jefferies. next comes Our Windley Dave

is open. line Your now

Dave Windley

XXXX. good. Good gating a morning. or to on little thanks. – timing Hi, quarter question. bit bookings the taking fourth in for through obviously, wanted bookings fourth of Thanks very the The the focus my of I quarter were

some for guidance XQ. us given You've

logical wouldn't could was seems guide you rest that I as think to in I gating growth kick quarter early as that through out of of as phases necessarily maybe the quarter. the it bookings year. the the first us fourth hoping the

Alistair Macdonald

to pass over Jason. Well, then I'll and start morning, I'll Yes. you Good Dave.

Dave Windley

Good morning.

Alistair Macdonald

saw preferred provider bookings our to in continued good needed progress good with Yes, we're through. bookings, saw very going we and that's with into awards QX. of QX XXXX. we Obviously, pleased quarter pipes and put We a starting good into large partnerships

to flow through So numbers into the we here continue we on expect go that from as to – out, I suppose.

in slow still obviously start, there but are those of to bookings Some everything in policy. with our line is

within So everything six months it on or starting comes in in. which months there kind of flavor depending is XX up the next

in did through, the to a across think job level yes, sector. that clinical. pleased see I fabulous a business, that bookings just not it's So we're broad right Michelle's team of work of QX in lot bringing and

the of the had got also, we've strength yes, of lot One. well. But always So in continue a in that Syneos saw as The from stuff flow to start we've small transactional those we the relationships. mid-market

growth. the Jason, So I of gating mean, the growth. all-round yes, terms in on good

Jason Meggs

the up same it, when that clinical going but really, that large second be looked X.X%, have that Yes, Dave, for are full limit very now, just would in going to to at we burning the second year previously half those cancellations backlog I in XXXX perform standing are accelerating talked that half. time, to will pharma an will the the And about year. that do is the similar mean, start offset when I we've those – growth clinical say, in partnerships how across up I've is have we we given in the did and to proportionately at

then won or the the is XX% first the that be this look medication in in the clinical we've with we in up at we through well XQ cancels, the in commercial, we XXXX and you bookings that of got do to is of these see, over however, we're pipeline XXXX. the as because coverage, going backlog commercial and the coming When beginning into to then as similar headwind pacing year and pipeline will then adherence – half, good from which get to

driving that of all is So that of sort pacing.

for XXXX commercial XXXX So when and for you I'd proportioning look think it. clinical at about

Dave Windley

partnerships are just awards, Okay. seems the those large starting which It a your common, like longer. common flow for those on of taken there pharma talked get recognition of with to quick kind thought has you about larger nicely. fairly from you've up. of now your stand pretty point experience kind pharma, follow-up into that that publicly with time then how also that a your stand we been as the longer it's And account little at has material taken of over been to to the bit that partnerships to that years, look up award and taken the guidance peers about Have has you revenue to them it If time of XXXX?

Jason Meggs

the the second been assets, already the we – guess, talked on partnership partnership in where some couple mean, those One or I Yes. I of – that doing about we working XXXX assets. we're on – talked would have we're third the the model Syneos a it about

So had good have we good behave – and, have going we obviously, know have a they're to and relationship of other visibility how to the really there assets. sort and

there a of we're expectations of the to news put And already clear. dates just that working four, we to where is the down, On that that be of the they had June have we quarter visibility good us. XXXX there. shaken in good about has and have slowed approvals as lot And loose. we talked partnership front of projects, ahead And several that the on protocol environmental the pipeline and the that we're factors in – the their

like the all given. we've feel we we yes, that factored guidance So into that

Dave Windley

Thank great. you. Yes, it. appreciate I

Alistair Macdonald

Thanks, Dave.

Operator

Thank you.

Our Credit Wright next question from Erin Suisse. with comes

line is Your now open.

Erin Wright

the thanks. can for new much guess I of the One terms in in was follow-up commercial consulting, you That quarter. kind us break How of would particular? break great. the Great, advertising wins? by versus Thanks. down down on bookings be that business A wins versus Syneos in CSO driven

Jason Meggs

Michelle Erin. look in towards we in. when in push Syneos – that I the in Hey, One that awards more at I chip talked about primarily mean clinical. and mid-January, start and you will can XXXX, I was think

we've that's commercial So seen the all be to one When awards businesses. had and big Syneos they getting what One, budgets going and we quarter are bookings quarter there know tend and what customers, to our across quarters POs good the quarter look four, you next year. in are across projects there. And they're and spend in the as and finalized renewed four with

delighted we performance business all segments, of units customer see were right different that So to good across frankly, too. across our the and,

us. for So was good finish it a

Michelle Keefe

Yes. is commercial our only I is a thing that in in Think nuance is that resonating with unique really integrated numbers see multi-capability, would model I of the QX. we just is, integration wins And the a you had kind lot reinforces of think that so add their can't important offerings. customers,

all So and consulting, communications and Deployment are they us to for integrated customers they're offerings feeding the where coming Solutions services. are but

a that's as know, and market believe where So the we we're starting to part pick really going, up. you that see of is big

Erin Wright

I And when progressing? that INC us rationale if heard much. the that then And merger, you about wondering give is up in and on that could update first quickly that haven't how announced, was the of about behind business front. inVentiv you great. an I really talk FSP. some it scaling was was Okay,

Alistair Macdonald

a FSPXXX, had of different we've rebranded to lot I mean, because services. we it Erin,

offshore well of very be do We people pharma, I have We We progress. et part, with to well. because different solutions, any large large inside shore we FSPs. our happy That in-sourcing Strong Paul, do own and well, different got that reach, as very do to it. of to think you can doing is choices points, a approach cetera. systems part thoughts. in key can as our drive full good that able working hybrids. big pharma We're we It's was additional price with on between balance I drive global pharma so build follow can large winning business a that it with was – work. as We've near placed hybrids. think, operational missing.

Paul Colvin

you've think I covered that.

can pharma think other FSP in we the is, mean, in provide that I the large for key appreciated. clients I services have they've XXX I nontraditional we some of some think provide customization some that enhancements our

Alistair Macdonald

on and at Erin, mean, well. that I time stuff like FSP and FSP we're road as conferences with talking all Yes. about the

clinical, customers. commercials selling big part across of a to are is to And us the selling focus the the we FSP it the then for or for key end overall service lot So still large integrated commercial obviously elements But top. large a – it's and to end. likewise on platforms clinical whether commercial,

– of what So foundation yes, of kind a it's clinical side. key a the we on do

Erin Wright

Okay, great. Thank you.

Alistair Macdonald

Thanks, Erin.

Operator

you. Thank

Tycho with next JPMorgan. question from Our Peterson comes

open. Your is now line

Tycho Peterson

Hey, thanks. I will clinical. start with

for it then going kind talk year Just And ramping deals you outlook quarters talk versus uptick and announced that we provider preferred forward? just front, deal can where preferred the on had just dynamic? the prior additional just burn in Can you declining. maybe maybe you how think the the been this about a to about of provider rate then nice

Alistair Macdonald

Yes.

Let you stuff. rate for me to pass then over and preferred start with burn Jason the and providers,

team we yes, the myself, couple Paul's that line large have team pharma of et sight, think, cetera. to and opportunities GCS a with and against more I So tracking we're

we So one done to that – I Creating help This Erin something target kind the be can to second of We're merger. scale large certainly about was that the largest CRO and now the efficiently is what talk imperatives another think invited we've to achieved. pharma talked one. that. is the that of created of

customers of is at more get are differentiation. what desire through. seeing that we're see discussions large right pharma I queue But So think to front a when brought we ever these our than the from

things, or We at model, in scale just can be it, we All everywhere wins the to show scale new you also, to the a are big pieces the want able in made whatever call go, So AiCure we Omnipresence. world. capability we service when people across where we big. have. to – the they we're that and innovation. Dynamic those into capital Assembly have new critical plugged need But Indegene are investments We're in critical we're

you If think plus them, the around win process, that had second depth. the the about we pharma capabilities and of clinical that to large therapeutic combination was plus commercial appeal trusted it

third last across how how you about dynamic model drive strategies it how we year, If from One, asset think the the one across, take it to, take was development all Syneos we paradigm. bring an about products we can and can asset drive a can them, capacity

very the created is achieved models that Assembly but through on enables the that. we've good us win. that integrating had and also platforms Dynamic about us So to we're differentiation imparities plug scale the the technologies, put gives to one just and from that data in at ground, data the and in It merger, through quickly. different there we this of the differentiation It's very different big we

I So future And provider positioned I that. we'll we're tracking of for bake-offs. be couple think preferred as well a say,

will that getting least at I a our on chances think C-cap. we fancy

confident on pretty the burn we're as yes, the we future. rate. into go So Jason

Jason Meggs

Yes, good morning Tyco.

ahead the that came is drove pickup burn cancels that in that backlog had in of reimbursement we the And and see the mathematics, did that then some quarter where in rate, the rate we you of experienced. burn down what September on So four. had of expenses given just the up come also we that expected right we yes, end

result we and we our and et the that cetera. we look at coverage I at check that and about forecasting to sequentially of lowest we as phasing burn one period, back strong look that back tick going start guys right, quarter in then And of think backlog each about at study what going will burn each look with average models. that's on rate we think it, you burn But know, XXXX down, your When that's rate. purposes a is when see, at rate it our you quarter ticking you throughout one you talk how our the to to up That's look to just sanity project – XX-month for at again, will quarter awards then come seasonally quarter. down. when sort

Tycho Peterson

just the right. headwinds following follow-up then and of David up pacing year, over on question on the just the And in you've adherence year. course half the got first All to earlier the the Windley’s medication commercial on of

As of we get headwinds the back the in assume that half? your end some adherence the that what to higher the about year, of of high recaptured half guidance, you medication guidance, think first the the in headwinds commercial end could the given X.X%, does of the

Jason Meggs

backup our of and off. affected already up adherence control Yes, already starting that so those of peeling medication of headwinds in The are some running. outside programs were by some the are issues technical

of to even suppose terms expect see pacing come we full to by QX, QX, of I in sooner. maybe up that So pace kind or

Alistair Macdonald

we and see when that's in XX% you're that's the hit of comes that stay pipeline and So, have. end and stronger to would in guidance have say we yes if going the see the the year, cancel that rate us With range. sort rates a a top into up for we that of year-over-year, given I strike Tyco strike high pipeline just play that getting start check to up

Tycho Peterson

Okay. Thank you.

Alistair Macdonald

Tyco. Thanks

Operator

Thank you.

next Barclays. from Jack question comes Our Meehan with

line now open. Your is

Jack Meehan

for reimbursed helped I the anything Was revenue Good equation And the that the during X.XX What know the of a trend clinical bookings I side. book-to-bill the XXX would chunky more, might side versus revenues quarter was the morning. the notably you hoping quarter. – bit have Thank could on there a the full basis? little year? influenced there book you. like on of unpack in the was

Jason Meggs

Jason Alistair. Yes, it’s hand Jack I'll then or to so Paul start, and over

said, you the the in starting XX across XX right. materially the revenue about up different, top to our segments we've when we performance see partnerships terms not mean, the we I have think there pick bookings and are look yes, So in although customer as of allocations, it's

is a weighted that. it towards So more little heavily

the strong. and SMID SMID there and everything pipe, However, remain and RPO, business,

of XXX those But we always the the look of that terms and law or you any of see XXX, at the a the land. we is what at X.X – we've In difference that two we requirements that talked we've look is measured. and period when less when land TTM XXX between reporting about

of not I you're what don't a huge details. terms Paul, to quarter. talk given more about And a know in difference that going see So any there in in if we

Paul Colvin

I mean, think I mean, I hit you well, Jason. it really

wins way. ramp think QX, about that they're think assets of XX of think, coming those seeing again, developing some the I top and in our we I when partnerships the

it's what's in any there. been from I we've So of the oncology haven't also seen to pipe. starting say, seen outside driven shift But see how of would work a normal in other up it's well. really pick that, lot we TAs And as

Jack Meehan

commercial what follow-up just then Tyco* terms to And Great. getting were and Dave the growth. at of on in

maybe lower what color full the Just think, a I range for of XQ little first just up just quarter end? in the because, you bridging X% give higher put the commercial, year, I full can into would terms heard bit just the steps you end And but of at versus the XQ? year to more versus X% right down to what

Jason Meggs

this was Deployment for – primarily obviously then Both that the as a on product, well impacted about the that about it’s And we've in their XXXX medication behind issue now. retailer business quarter that with, That a us Yes, quarter in that Jack cancels one four. by of as adherence with we exacerbated of had breaches. issue supply three situation are Solutions. those was issues data talked we talked

there one quarter However, we second into we of something get items. both the the see makes pacing, year, start things as laughing what still When that of half we for over is of to to those the for XXXX. carry I those a similar in said and

higher to going do is more a that to see in With so and normalized rate stay like us well we pipeline check of up as to where back of end where pipeline we the here strike that's sit in level, drive sort on if cancels higher ended our you're today, I – relative said, that XXXX the drive range. go we the a where they it if higher

Jack Meehan

Thank you, Jason.

Jason Meggs

welcome. You’re

Operator

you. Thank

question Our next with SunTrust. Sandy [ph] Fraser comes from

is line now Your open.

Unidentified Analyst

Thanks very much.

know of but mean slides most says couple have asked. maybe FX FX sorry of been still in a XXXX? I – at or benefit I any drag there's of footnote as we Just into XXXX the questions, FX it big from questions material December assuming there XX, my housekeeping a head picture is

Jason Meggs

Paul?

Paul Colvin

Sandy. hey Yes,

and a are point. So XX at that was of the as rates December push there basically

$XX or something million now we it think, there's, that. As look at like I headwind a approximately right

point, we that's material going to but like eye at it. an So enough felt we're about talk keep this not to on

Unidentified Analyst

sort no share helpful. also down think great. of said you have you use remind thinking of dealt a in repurchase repos? priorities back then table know can the into thinking M&A about, debt, left follow-up, you're as about and don't That's much I about how how me noticed you the terms then you paying little XXXX? on about Okay, if is further model, of And the the one, talk cash

Jason Meggs

the left through approval $XXX and in goes XXXX… that we think the of end I have million

Paul Colvin

year. This

Jason Meggs

And the We're we got to priorities the times. target at are X.X as that we would. We were. down said they leverage

Aaron's drive We’ll model, come can I to add I We we the if about that that. give debt flexibility. with like happy to remember we’re this to But maybe some So delever priority. answering things said that along question can't was Dave want a us down I as differentiation. before then and or continue

models keep got You've these moving. to

first first start same. sharp do out the The market the there need we you got bringing day we new the some on to so something they're to always dying. competitors day the move, are you not And as

add therapeutic see is to it's we whether opportunities model, repurchase we've for us. to the share list a that probably at on a the capability, tech specialty, the next if third priority and then So looked as

Alistair Macdonald

Sandy to Yes. And X set we target end XXXX just the add the leverage to X.X, that of times.

the cash on each the… – share and to going have focused year available we're the And repurchases, that at we're So still take on – very that's assuming to we the to the look then priority.

Jason Meggs

Dilution.

Alistair Macdonald

options the stock and off market. from the Dilution the restrict

So that's the plan.

Unidentified Analyst

much. so Thanks Great.

Jason Meggs

Thanks Sandy.

Operator

you. Thank

Our Robert with Goldman next from Sachs. question comes Jones

open. Your now line is

Robert Jones

more as as for you FSP be it bookings and that'd around far We've offering share recently. talked about to Thanks early wondering go any could questions. more today? part if that the much feedback have you the heard first positive drive XXX. how back the want guys know is the I'm Great. question. I So some of to helping there's I of

continue the of wanting part versus service to you optionality second strike do your obviously to to And customers, about win work? FSP that balance is XXX full flexibility how as the we more think between offering

Alistair Macdonald

Well, Paul?

Paul Colvin

as ways think service Each a don't full if a plates. in take them large different in in regionally, I become I their different stage and are off There the again more you as this can create as difference as well solution? support between do. about The their think do pharma each XX. way work especially much we I FSP potentially, How splits about therapeutically. top of non-traditional pharma of can a is tasks pipeline, have really view customized we we this larger that the is is they

at looking by they the assets all assets to that the the of top priority across we've them real So that allows globe, some have to targeting give cover them nontraditional been that that offering to do lower their of to they priority from path develop. have to the a

and non-core as needs what I that's of about tasks don't solution think So some with nontraditional, FSP and try their either/or, we have an helps they the that view really FSP. it’s this them And it hybridized XXX. them an fill to into really put take

Alistair Macdonald

Yes.

Robert Jones

can And then driving give of that? around bookings, kind how color much any you is

Jason Meggs

Jason. it’s Bob hey, Yes,

good. XXXX, we when in business large about one that been a the look you in FSPXXX. of it's the meaningful that when partnerships, that announced you is So these at There's right? portion And that particularly growth think

in these involved in those winning it's So awards bookings relationships. move and as we then the through

Alistair Macdonald

add bring they're build tremendous under and pressure bit I pressure. that down FSPXXX little is tremendous they’re When cost we sit too. Obviously flavor of the and those through the can those lot provides? nearshore, the want, price pass scale – in is with that discounts what it customers, talk them platform drives what well so that economies I’ll reach a it to what a we combinations, a the of them, to economies under are just can Bob, about Yes, to that And being able offshore, through customer. efficiencies, is that all through they are

see you the then fully. them products that that in if high drugs would big through the the But we pipe FSP coming way science complex delivered get very lost that

clinical FSP, be ground got you a in delivering project speed, position the to data can crisp, the therapy. where precise, all of put very project be that up Yes, but that's on the that's team and really that around to in very medical need have that through style. the it still sharp, management, the monitoring experience monitoring top plug on to able So to the leadership, very you a the

those got having you've to So build to oscillate down together an the and up pieces and ability model.

bit. large go don't FSP little and They full in go swing to the Our customers of oscillate around and a don't service. they kind middle full

defense to hybrids. and way, play to go, go these So part whichever well either go a way build ability as they having want the of what you to when it's that's each

Robert Jones

ten No, around said just And guess I you follow-up you if million heard in helpful. Coronavirus, Jason, headwind to correctly, I my five that's really XQ.

Just EBITDA? there wondering next to the guidance ex-QX? headwind for through droped in balance much or of straight the then of that was is any in And baked how contemplated year

Jason Meggs

Yes.

reimbursable. of Bob, some that, there's associated So that's with

about then if I what is way to it studies it's And And just XX% on obviously, in keep look sort headwind. quarter now we et a I'm what contained being know, at and as mitigation cetera, XX%, to on think planning, it of right, this on we it now based we're exactly is, drop-through to sufficient. stays right China, trying going one So moving, understand believe we would what's the EBITDA. that it we see

Alistair Macdonald

Yes.

Jason Meggs

However, see and other out. see. have to now, see region just impact and quarter countries what one we'll But if it just plays right it's to we broader how starts the it

Robert Jones

thank Got it, you.

Alistair Macdonald

Bob. Thanks

Operator

Thank you.

Dan UBS. Our next with question comes from Brennan

Your is now open. line

Dan Brennan

a the in few from the much? you know clinical large strong that the trying were impact on there are to they Thanks just wanted very contributed understand how strong well questions quarter, I'm you partnership much to front. to as the on the that three figure a the asked I book-to-bill I commercial, would but bit for tease fourth quarter So out really really to book-to-bill question. But out deviate pharma signed, little this as if obviously, book-to-bill?

Alistair Macdonald

to those a said as we as as SMID large foundation run like broad-based, Yes, in I We mean, large your it's the well uplift you of small pharma. built pharma the you quarter the relationships see bookings in successful be mid-sector. the I But the bookings. very point I they think, really before, in so in to the did small to do mean, revenue. mid. well in the in still I got every the

So going break to or you down from can things obviously, all But day. we're subsectors these assume some and of it not to is, here out we'd that large that be uplift partnerships.

would contribute said that's But mean, in We large yes. to the happen, partnerships to pharma we what I start right? QX. were said we expecting

through get get the of ahead control the money think setup delays will through the curve place, those coming to and they continues data flow. to degree. factors the we've stream. XXXX yes, get connections there to are that's And had, to first investment tech partnerships and start the environmental as that systems, XXXX all the have all outside made our well one spending into that the But in into in ready, We of teams on I to we some

Dan Brennan

that's in you've how whether in more north $X a towards One? – Syneos And terms in but And that may little potential just well on a XXXX you I actual potential there what's pipeline. kind may cumulative share Thank as just give from $X.X is Great. of of out? rolled remarks, Thanks then can the kind flavor have bigger of interest Alistair. to I of you've it billion potential level capture customers, stand One, of to for evolved you. know beyond? as be or missed what billion, follow-up, update prepared begin that in discussed the any Syneos backlog the And

Alistair Macdonald

Dan. we other the going IT big business we expect it work should to all right The get the if get It development it don't $X.X would went the the that that's through make make direction work work should much a piece go is its right? that in is that end. it happen. product easier way funded, contingent reason approval, that's on that all a the out you little doesn't all model, model. it approval. leave the came billion point through me to because every way But journey, products of let product to So launch, a that Yes, into committed The of bit, through value that be all just those

So fall we products some to by of wayside. those expect

not we line so we don't because book keep it's in with So it contingent. policy, it our bookings

not therapeutic that billion. functional, the So the them market with small – This that's attack playing not optionality as a to tool The small a to functional, than the is $X.X market the that we is as business much the them give units. model bigger to the mid that. as in different we're take so well the well through

all in way commercial. So actually just but we through the around how those develop clinical attaching Syneos not optionality customers us One gives

bigger well-capitalized us bigger that market. trying pull attractive their the the to because It's the capability drug to we in on to only people we is are platform a relationship. there's actually So and making – this through, people way all given market. very with to specialty with We're can this hold a which We're capability, obviously products.

massive don't You teams sales backlogs. diversify is us helping to which commercial need also for the it,

I Paul? So mean additional any thoughts

Paul Colvin

talked just awards, XXXX. of $XXX we total about gone backlog, that billion of potential during million we've mid-January over I awards the on think Dan, Yes, backlog that have I and would into in say, $X.X had that the

gone in $XXX went that in but years, has into And far it's what's the lower bit far XXXX. prior than XXXX. But million in of that a was there. sort that's in lower backlog So there it's

are commercial going make assets five next so most Alistair the as see we And is but building are continuing on We that, PDUFA know those some those focus that approval clinical, will because we're up what it. do drive three to then, can to over years. that And some backlog aren't there going we're right have going are, XX make and the to in mentioned, pipeline it, there to into be management killed when about that's getting is strong. get under That dates piece that's dates the now. to excited some we

of So commercial assets in we're going the the for to more managing, the over visibility years. better terms be that's

Dan Brennan

Great. Thanks a lot.

Paul Colvin

Thanks Dan.

Operator

Thank you.

Our from next question comes with Donald KeyBanc. Hooker

is line Your open. now

Donald Hooker

the on better to a I the growth. economics sense revenue get wanted Great. incremental of

on which should for You of margin guys, basis relationships, XX XX sort of materially? I EBITDA believe, think you to probably of kind commented, to of expansion is expanding points a think I couple is some assume a EBITDA it But basis above I assuming, dilutive. normalized margin that points ramped, and annually think, these basis incremental fair be of provider large more of I kind are pharma years. XX preferred when these That's things also

Jason Meggs

hey Jason. it’s Yes, Don

do nothing headwind When starting to partnerships market there specifically more, see want haven't growth, potentially, and that the mentioned, look go. We have up as can the be in those start now material. We flow think right? add to we could experienced investing and additional were opportunity revenue at we model. that's we when assumed set short-term we headwind our Alistair new XXXX you partnership we've the the some like three, in had, a through visibility as but large partnerships over where We we to we

right, top don't if headwind longer And of have of ours, at are customers the when a competitors have margins. see a our a top XX, longer they you who strong in term. at large as it very business look book we five these of term, ten being margins can we as volume very competitive, be believe or top But so you're that some

So it's and getting stood that just about volume up in. efficiently getting them

Donald Hooker

I follow-up. wanted strategy. more about little your hear bit And a Okay. quick CRM then a to maybe

in believe. this that Why relationships sort partnership of And your impact how You investing a does there, there? an you of investment software and other company? in – announced I can you the are sort company equity other

Alistair Macdonald

to this we that we differentiation. looked we're partner the I about talking saw be can capability us, have make they a it, for in much very to call in more in the a at we market. said question doing, enhanced stable. it platform when were Syneos attractive enables bigger, because them a We potential. more believe teams, to – through in I which model, with I the that set Assembly Dynamic remember platforms mean, us opportunity that to in new And is We what think like to them for capable, be – for it bring great investments Yes. effective like this care more we health an invested has the think our looks Microsoft space. wants good

teams providers. give health platforms our can and and and service So they good data jobs the that we and try get we and out tools, a can master best and so systems their better it fulfillment out give of to customers their care

a part And making the patients. us, is is is to model access, For getting getting big understand access – patients care sure health is for our bringing of providers more. drugs access the

providers. You don't new these care to health drugs sell

provider the health get effectively. they their to us Omnipresence for the to help patients them. and identify absorb care educate them so channels, can platform effective information most You best the per channels And data to most treat that them will

or to… Michelle And that's want Paul simple, pure and you

Michelle Keefe

Sure.

CRM Dynamic our right, strategy, multiple back go with Assembly So to work when you providers. we

choosing you the that to that So right? our we our first that’s opportunities to thing think I partners the is we're do. take that. trying be know advantage make of most strategy, I customers, that – for mean, going for the basically sense always first

is The think Omnipresence do second best to in like realtime it is for on because see around predictive analytics is customers. tool give built them engine we think we out And important of we our is AI huge the thing to there a to is Omnipresence top Microsoft, that I reason unmet marketplace need the that, the the that's right?

you as we know, omnichannel an have so And strategy.

we another they that with are a see toolbox, creating because was this see we an we tool have it, interest need to market that unmet just from and a We Omnipresence partnering in our want in as of. niche unique in like of the take putting ton customers advantage that

Donald Hooker

Okay, thank you.

Operator

Thank you.

Our Anderson ISI. Evercore question comes with from next Elizabeth

now is Your line open.

Elizabeth Anderson

to guys. to Hi, the for we that expansion biggest wondering areas about back could I – is if the in question referring that do taking XXXX. margin What areas Thanks talk was the [Indiscernible]. investment good just you morning commercial you see question. the there? the back have European impact you

Alistair Macdonald

hit, I bit little – had but we've to earlier a harder on. a It’s similar question

we're So the platforms. like out around – country solutions, consulting, as deployment that communications, terms Europe by of we growing med, in comms, things roll harder but global more that, difficult in country it's

So in elements be Europe communications the work commercial us typically well. focus of for terms investment And and higher-margin of as commercial will that are consulting. they yes, in in the

Elizabeth Anderson

a of how more So that should of So like sounds it we're sort as about we like modeling? of process? it's multiyear that’s investment sort think

Alistair Macdonald

build and had hand your that basis, throw the see on platform out a been monthly we lot. us, have XXXX. ground. mean, buying platform sims around mean, That's it's can shops consulting Because on with I careful the but – to don't to like stuff bought We're I how a you sometimes. many and in which in successful be gave us pretty the Yes, absolutely. But we for we've already consulting that. I gosh, Kinapse good But a know Europe. yes, communications

just seen just So do, a organic not we we've that add-ons revolutionary and kind there. growth thing. It's transformational adding we're It's to good on it. of

Elizabeth Anderson

Okay, perfect. Thank you.

Alistair Macdonald

Thanks Elizabeth.

Operator

Thank you.

comes question with from Donnelly Citi. Patrick next Our

is line Your now open.

Patrick Donnelly

Thanks. Maybe just a couple for Jason.

can XXXX, these XXXX. some just one on the things costs some got partnerships, like year? last of Is these the talk through in ramp with those of that to think I hiring, help from expectations margin given of some cost on big going forward on large front costs that that? Just you you incurred pulled some the to

Jason Meggs

yes, is that's how we're a It's up. put right? to base about We it, of partnership I starting Yes. stand investment. thinking exactly in – That mean,

have types partnerships. different of We

infrastructure around and flexible needed partnership a what run of partnership. how that the more bit wanted it an to us for given be they customer their to So to do we particular has little

go ensure The our deliver associated lines, have less them. with that therapeutic to time. already down but two infrastructure have, that will more we They'll other hire on the ahead business infrastructure we we

now, the And as we're of the partnership, we KPIs earlier is mentioned ahead we're good subprojects I that news running three on the have.

pleased we're with So that.

new base think year. we way dropping in layer that the that's then and it, the start is about over in So that, now partnerships we'll

Patrick Donnelly

in more Okay. color the And than then give on just XXXX can there? maybe savings next Which initiatives, the on a pulling incremental bit levers cadence you ForwardBound some year? of rather of just the you're

Jason Meggs

Sure. Yes.

So in ForwardBound getting we driving XXXX, QX And of savings in expansion points basis to launched XX so at. XX of that that part we are that's XXXX. we're of

business at The first looking order the of the model. is evolution continued of

many the turned do it's, a There's little XXXX. got page integration in integrated. in we've many in right? work more to So we've okay, on respects, But respects,

That SG&A where be Now we're resources we commercial that at going can on model And model. that to That and optimize in the the have focus let's four opportunity for grow headcount how the an model. can model. have to delivery we look clinical we delivery be and sites the globe the the that have around lower-cost can be that.

areas So going we're sales growth, the operating up percent the that of out do and that's track leverage of to and in as is the the the the as will said, look, So leverage, it's order at whether or to move well growth, pieces business. of grow of need cost you revenue of good the operating with revenue business, right? expectation not X that, that that's business for sort of SG&A, fixed cost the first XXXX we've

those focused on. So areas that the are first we're two

Patrick Donnelly

it. appreciate I

Operator

Instructions] comes next Stephen Wolfe Thank you. from Our [Operator question with Research. Baxter

is line now Your open.

Stephen Baxter

mix, looks year. customer And the slides revenue nearly Hey like the good this your From it SMID question. was growth morning. thanks XX% your across on company past in for

think pharma So understand the this that about to you've guidance evolving relative expectation. should in SMID your the growth for to large you're and for how look wins business XXXX? clinical as then is XXXX, had for trying how And at the to that particular, we planning your we relative with

in Thanks. that those to going burning start discussed near are relative the wins future. You

Jason Meggs

that focused mean, Yes, on clinical ahead. so we given SMID XXX. SMID, we're picking this that have. focus mentioned, it’s it new the and move market. we as with like I great really under-indexed know, thesis And and We the continue to the That I a said, very about Jason. where our partnerships the these strategy on be SMID side, as we That’s hi we been, the to to has see that's been. we pharma had the our SMID, talked do as up backlog particularly in pipeline merger the to our But same penetrate top has heritage, you compared right. and SMID year news, earlier is XX FSP continue on

the merger we have that that was mind. and thesis SMID we're commercial, in that of mix Another would driving schedule had SMID into key component the behavior customer seeing ahead and happen well of

will XXXX Is growth. there up large Stephen? but partnerships the growth pharma of all anything? on show start focused that else those there to in we're So in it, Is anything

Stephen Baxter

that I’m you. all with said Thank one.

Alistair Macdonald

All thank you. right,

Operator

to not remarks. any for I'm you. closing Thank any at over Alistair like back would time. I the this call turn showing to questions further Macdonald

Alistair Macdonald

Well, Okay. say everybody, to investment just in interest like organization. and I'd thank attendance and you, your for today the

day, So good. Thank and you. good wish be a you

Operator

Ladies and today's you participating. gentlemen, concludes Thank this for conference call.

You disconnect. may now

Syneos Health (SYNH) 20 Feb 202019 Q4 Earnings call transcript